Skip to main content
SpringerLink
Log in

Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hollifield AL, Arnall JR, Moore DC (2020) Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. Am J Health Syst Pharm 77(15):1201–1207

    Article  Google Scholar 

  2. Zheng XL, Vesely SK, Cataland SR et al (2020) ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2486–2495. https://doi.org/10.1111/jth.15006

    Article  Google Scholar 

  3. Elverdi T et al (2021) Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy? Expert Rev Clin Pharmacol 14:1183–1188

    Article  CAS  Google Scholar 

  4. Peyvandi F et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511–522. https://doi.org/10.1056/JENMoa1505533

    Article  CAS  Google Scholar 

  5. Scully M et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335–346. https://doi.org/10.1056/NEJMoa1806311

    Article  CAS  Google Scholar 

  6. Peyvandi F et al (2017) Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 15:1448–1452. https://doi.org/10.1111/jth.13716

    Article  CAS  Google Scholar 

  7. Dutt T et al (2021) Real-world experience with caplacizumab in the management of acute TTP. Blood 137:1731–1740. https://doi.org/10.1182/blood.2020007599

    Article  CAS  Google Scholar 

  8. Tse B et al (2020) Describing the point prevalence and characteristics of venous thromboembolism in patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2870–2877. https://doi.org/10.1111/jth.15027

    Article  CAS  Google Scholar 

  9. Picod A, Veyradier A, Coppo P (2021) Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab? J Thromb Haemost 19:58–67. https://doi.org/10.1111/jth.15194

    Article  Google Scholar 

  10. Benhamou Y et al (2020) Venous thrombo-embolism during immune-mediated thrombotic thrombocytopenic purpura is prevalent in patients with a prolonged treatment with therapeutic plasma exchange. La Revue de Medicine Intern 41:809–813. https://doi.org/10.1016/j.revmed.2020.06.014

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Specialty Pharmacy Service, Atrium Health, 4400 Golf Acres Drive, Building J Suite B1, Charlotte, NC, USA

    Benson Meek, Thuy Tran & Justin Arnall

  2. WakeMed Health and Hospitals, 3000 New Bern Avenue, Raleigh, NC, 27610, USA

    Nuti Desai

  3. Levine Cancer Institute, 1021 Morehead Medical Dr., Charlotte, NC, 28204, USA

    Donald C. Moore & Mary Ann Knovich

Authors
  1. Benson Meek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nuti Desai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donald C. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thuy Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mary Ann Knovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Justin Arnall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Justin Arnall.

Ethics declarations

Research involving human participants and/or animals

N/A. This is a case report of therapy selection and response to therapy outside of a clinical trial. This article does not contain any studies with human participants performed by any of the authors.

Informed consent

N/A. Institutional review board reviewed, and patient consent identified as not required.

Conflict of interest

Donald Moore has served on advisor boards for Pfizer, AstraZeneca, and Janssen. Justin Arnall is supported by Novo Nordisk (Hemophilia) Speaker’s Bureau, CTI Biopharma Advisory Board. The rest of the authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meek, B., Desai, N., Moore, D.C. et al. Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura. Ann Hematol 102, 457–459 (2023). https://doi.org/10.1007/s00277-022-05049-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-05049-6

Keywords

Search

Navigation